Die Cumulus-Oozyten-Regulationsschleife und deren Bedeutung für die Reproduktionsmedizin

Zusammenfassung

Die Interaktionen zwischen der Oozyte und den Follikelzellen sind Gegenstand der Forschung. Auf der Basis der Grundlagenforschung und erster klinischer Erfahrungen wird die Bedeutung der Cumuluszellen für die Oozyte im Rahmen einer IVF/ICSI Behandlung diskutiert. Durch die Verbindung der Cumuluszellen mit der Oozyte über Gap junctions ist ein bidirektionaler Austausch von Botenstoffen möglich, der zu einer optimalen Entwicklung der Oozyte beiträgt. Als Botenstoffe spielen bei der Oozytenentwicklung FSH, LH und EGF eine wesentliche Rolle. Außerdem produziert der Cumulus-Oozyten-Komplex Botenstoffe, die die Spermatozoen anlocken. Die Apoptose der Cumuluszellen und das Anti-Müller-Hormon können möglicherweise als prädiktive Faktoren für reproduktionsmedizinische Therapien genutzt werden. Es wird dargestellt, welche Rolle GnRH, FSH, LH und Estradiol (E₂) bei der Oozytenreifung im Rahmen der bidirektionalen Kommunikation zwischen Cumuluszellen und Oozyte spielen. FSH und LH sind wichtige Faktoren für die Follikulogenese und Oogenese. Für FSH und LH scheinen Schwellenwerte zu existieren, die die Oozytenqualität und letztendlich die Schwangerschaftsrate beeinflussen. Die retrospektive Subanalyse einer vergleichenden Studie, in der hMG-HP mit rFSH verglichen wurde, zeigte, dass die hMG-HP-stimulierten Zyklen nach vorhergehender Downregulation mittels GnRH-Agonisten in IVF-Patientinnen zu einer signifikant höheren Schwangerschaftsrate führte als mit rFSH. Weitere prospektiv, randomisierte Studien müssen jetzt klären, ob durch die Cumulus-Oozyten-Kommunikation IVF-Patientinnen stärker von einer Stimulationstherapie mit hMG-HP profitieren als von einer rFSH-Behandlung in Bezug auf die Schwangerschaftsrate.

Abstract

Interaction between oocyte and follicle cells, cumulus oophorus and theca cells is the subject of research. Based both on fundamental research and first clinical experience, the role of cumulus cells for the oocyte within the framework of IVF/ICSI treatment is discussed. The connection between cumulus cells and oocytes via gap junctions makes the bidirectional exchange of chemical messengers possible. This exchange, in turn, contributes to the optimal development of the oocytes. FSH, LH and EGF as chemical messengers play an important role with regard to the development of oocytes. Furthermore, the cumulus-oocyte complex produces chemical messengers which attract sperm. The extent to which both the apoptosis of cumulus cells and the anti Mullerian hormone can be used as predictive factors for ART is discussed. The role that GnRH, FSH, LH and estradiol (E2) play in oocyte maturation within the framework of the cumulus-oocyte complex is described. FSH and LH are important factors for folliculogenesis and oogenesis. Threshold effects appear to exist for FSH and LH which affect oocyte quality and ultimately also pregnancy rate. The retrospective subanalysis of a comparative trial with hMG-HP vs. rFSH in GnRH agonist downregulated ovarian stimulation cycles showed that the hMG-HP stimulated cycles led to a significantly higher pregnancy rate among IVF patients than did those with rFSH. Further prospective randomized studies must now clarify whether, as a result of cumulus-oocyte communication, IVF patients profit more from hMG-HP stimulation than from rFSH with respect to pregnancy rate.

Cumulus-Oozyten-Komplex - prädiktive Faktoren - Apoptose - Anti-Müller-Hormon - GnRH-Agonist - Gonadotropine - FSH - LH - IVF

Cumulus-oocyte complex - predictive factors - apoptosis - anti Mullerian hormone - GnRH agonist - gonadotrophins - FSH - LH - IVF

Literatur

• 1 Eppig J J. Oocyte control of ovarian follicular development and function in mammals.  Reproduction. 2001;  122 829-838
• 2 Webb R J, Bains H, Cruttwell C, Carroll J. Gap-junctional communication in mouse cumulus-oocyte complexes: implications for the mechanism of meiotic maturation.  Reproduction. 2002;  123 41-52
• 3 Van Soom A, Tanghe S, De Pauw I, Maes D, de Kruif A. Function of the cumulus oophorus before and during mammalian fertilization.  Reprod Domest Anim. 2002;  37 144-151
• 4 Hunter R H. Sperm: egg ratios and putative molecular signals to modulate gamete interactions in polytocous mammals.  Mol Reprod Dev. 1993;  35 324-327
• 5 Van Soom A, Tanghe S, De Pauw I, Maes D, de Kruif A. Function of the cumulus oophorus before and during mammalian fertilization.  Reprod Domest Anim. 2002;  37 144-151
• 6 Salustri A, Camaioni A, D'Alessandris C. Endocrine and paracrine regulation of cumulus expansion.  Zygote. 1996;  4 313-315
• 7 Salustri A, Yanagishita M, Hascall V C. Synthesis and accumulation of hyaluronic acid and proteoglycans in mouse cumulus cell-oocyte complex during follicle stimulating hormone-induced mucification.  J Biol Chem. 1989;  264 13840-13847
• 8 Host E, Mikkelsen A L, Lindenberg S, Smidt-Jensen S. Apoptosis in human cumulus cells in relation to maturation stage and cleavage of the corresponding oocyte.  Acta Obstet Gynecol Scand. 2000;  79 936-940
• 9 Alisch A, Ruping K, Koster F, Schopper B, Baum M, Finas D, Felberbaum R, Dor S, Al-Hasani S, Diedrich K. Cumulus cell apoptosis as a predictor for oocyte quality in artificial reproduction technique.  Zentralbl Gynakol. 2003;  125 452-457
• 10 Al Hasani S, Abu-Hassan D, Köster F, Schöppe B. Comet assay of cumulus cells and spermatozoa DNA status and relationship to oocyte fertilization and embryo quality following ICSI. 19th ESHRE Annual Meeting 29. 6. - 2. 7. 2003 Madrid. 
• 11 Clavero A, Castilla J A, Nunez A I, Garcia-Pena M L, Maldonado V, Fontes J, Mendoza N, Martinez L. Apoptosis in human granulosa cells after induction of ovulation in women participating in an intracytoplasmic sperm injection program.  Eur J Obstet Gynecol Reprod Biol. 2003;  110 181-185
• 12 Mikkelsen A L, Host E, Lindenberg S. Incidence of apoptosis in granulosa cells from immature human follicles.  Reproduction. 2001;  122 481-486
• 13 Schröder A K, Katalinic A, Griesinger G, Diedrich K, Ludwig M. Kumulative Schwangerschaftsraten und Therapieabbrüche bei Patientinnen ≥ 40 Jahren: 394 Zyklen bei 151 Patientinnen.  Geburtsh Frauenheilk. 2004;  64 723-729
• 14 Schröder A K, Pelikan S, Tauchert S, Griesinger G, Felberbaum R, Diedrich K. Prognostische Faktoren für den Erfolg einer intrauterinen Insemination: Eine Evaluation von 1005 Zyklen bei 349 Frauen.  Geburtsh Frauenheilk. 2004;  64 1052-1060
• 15 Munz W, Seufert R, Wulgaris S, Schaffrath M, Pollow K. Altersabhängige Serumkonzentrationen von Inhibin A, Inhibin B und Aktivin A bei jüngeren und älteren fertilen Frauen.  Geburtsh Frauenheilk. 2003;  63 1027-1031
• 16 Welt C K, McNicholl D J, Taylor A E, Hall J E. Female reproductive aging is marked by decreased secretion of dimeric inhibin.  J Clin Endocrinol Metab. 1999;  84 105-111
• 17 Muttukrishna S, Child T, Lockwood G M, Groome N P, Barlow D H, Ledger W L. Serum concentrations of dimeric inhibins, activin A, gonadotrophins and ovarian steroids during the menstrual cycle in older women.  Hum Reprod. 2000;  15 549-556
• 18 Hall J E, Welt C K, Cramer D W. Inhibin A and inhibin B reflect ovarian function in assisted reproduction but are less useful at predicting outcome.  Hum Reprod. 1999;  14 409-415
• 19 Casper F W, Seufert R J, Schaffrath M, Pollow K. Concentrations of inhibins and activin in women undergoing stimulation with recombinant follicle-stimulating hormone for in vitro fertilization treatment.  Fertil Steril. 2001;  75 32-37
• 20 Creus M, Penarrubia J, Fabregues F, Vidal E, Carmona F, Casamitjana R, Vanrell J A, Balasch J. Day 3 serum inhibin B and FSH and age as predictors of assisted reproduction treatment outcome.  Human Reprod. 2000;  15 2341-2346
• 21 Te Velde E R, Pearson P L. The variability of female reproductive ageing.  Hum Reprod Update. 2002;  8 141-154
• 22 van Rooij I A, Broekmans F J, te Velde E R, Fauser B C, Bancsi L F, de Jong F H, Themmen A P. Serum anti-Mullerian hormone levels: a novel measure of ovarian reserve.  Hum Reprod. 2002;  17 3065-3071
• 23 Cohen-Bacrie P, Hazout A. Follicle stimulating hormone and inhibin B in the woman.  Gynecol Obstet Fertil. 2001;  29 320-323
• 24 Wu J, Nayudu P L, Michelmann H W. Luteinizing hormone has a stage-limited effect on preantral follicle development in vitro.  Biol Reprod. 2000;  63 320-327
• 25 Oussaid B, Mariana J C, Poulin N, Fontaine J, Lonergan P, Beckers J F, Cognie Y. Reduction of the development competence of sheep oocytes by inhibition of LH pulses during the follicular phase with a GnRH antagonist.  J Reprod Fertil. 1999;  117 71-77
• 26 Chen H F, Shew J Y, Chao K H, Chang L J, Ho H N, Yang Y S. Luteinizing hormone up-regulates the expression of interleukin-1 beta mRNA in human granulosa-luteal cells.  Am J Reprod Immunol. 2000;  43 125-133
• 27 Byskov A G, Yding Andersen C, Hossaini A, Guoliang X. Cumulus cells of oocyte-cumulus complexes secrete a meiosis-activating substance when stimulated with FSH.  Mol Reprod Dev. 1997;  46 296-305
• 28 Zelinski-Wooten M B, Hutchison J S, Chandrasekher Y A, Wolf D P, Stouffler R L. Administration of human luteinizing hormone (hLH) to macaques after follicular development: further titration of LH surge requirements for ovulatory changes in primate follicles.  J Clin Endocrinol Metab. 1992;  75 502-507
• 29 Anderiesz C, Ferraretti A, Magli C, Fiorentino A, Fortini D, Gianaroli L, Jones G M, Trounson A O. Effect of recombinant human gonadotrophins on human, bovine and murine oocyte meiosis, fertilization and embryonic development in vitro.  Hum Reprod. 2000;  15 1140-1148
• 30 Baird D T, McNeilly A S. Gonadotrophic control of follicular development and function during the oestrous cycle of the ewe.  J Reprod Fertil Suppl. 1981;  30 119-133
• 31 Shoham Z. Treatment of female infertility with recombinant human luteinizing hormone: is there a benefit over other available drugs?.  Expert Opin Pharmacother. 2003;  4 1985-1994
• 32 Westergaard L G, Erb K, Laursen S B, Rex S, Rasmussen P E. Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: a prospective randomized study.  Fertil Steril. 2001;  76 543-549
• 33 Fleming R, Chung C C, Yates R W, Coutts J R. Purified urinary follicle stimulating hormone induces different hormone profiles compared with menotrophins, dependent upon the route of administration and endogenous luteinizing hormone activity.  Hum Reprod. 1996;  11 1854-1858
• 34 Westergaard L G, Erb K, Laursen S, Rasmussen P E, Rex S. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.  Hum Reprod. 1996;  11 1209-1213
• 35 Kolibianakis E M, Zikopoulos K, Schiettecatte J, Smitz J, Tournaye H, Camus M, Van Steirteghem, Devroey P. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF.  Hum Reprod. 2004;  19 2490-2496
• 36 Humaidan P, Bungum L, Bungum M, Anderson C Y. Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation.  Hum Reprod. 2002;  17 2016-2021
• 37 Kolibianakis E M, Albano C, Camus M, Tournaye H, Van Steirteghem A C, Devroey P. Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: Effect on hormonal levels and follicular development in in vitro fertilization cycles.  J Clin Endocrinol Metab. 2003;  88 5632-5637
• 38 Canipari R. Oocyte-granulosa cell interactions.  Hum Reprod Update. 2000;  6 279-289
• 39 Vanderhyden B C, Telfer E E, Eppig J J. Mouse oocytes promote proliferation of granulosa cells from preantral and antral follicles in vitro.  Biol Reprod. 1992;  46 1196-1204
• 40 Platteau P, Smitz J, Albano C, Sorensen P, Arce J C, Devroey P. Exogenous luteinizing hormone activity may influence the treatment outcome in in vitro fertilization but not in intracytoplasmic sperm injection cycles.  Fertil Steril. 2004;  81 1401-1404
• 41 Malekshah A K, Moghaddam A E. Follicular fluid and cumulus cells synergistically improve mouse early embryo development in vitro.  J Reprod Dev. 2005;  51 195-199
• 42 Magier S, van der Ven H H, Diedrich K, Krebs D. Significance of cumulus oophorus in in-vitro fertilization and oocyte viability and fertility.  Hum Reprod. 1990;  5 847-852
• 43 Hassan H A. Cumulus cell contribution to cytoplasmic maturation and oocyte developmental competence in vitro.  Assist Reprod Genet. 2001;  18 539-543
• 44 Kidder G M, Mhawi A A. Gap junctions and ovarian folliculogenesis.  Reproduction. 2002;  123 613-620
• 45 Matzuk M M, Burns K H, Viveiros M M, Eppig J J. Intercellular communication in the mammalian ovary: oocytes carry the conversation.  Science. 2002;  296 2178-2180
• 46 Al-Inany H, Aboulghar M, Mansour R, Serour G. Meta-analysis of recombinant versus urinary-derived FSH: an update.  Hum Reprod. 2003;  18 305-313
• 47 Van Wely M, Westergaard L G, Bossuyt P MM, Van der Veen F. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles (Review).  The Cochrane Collaboration. 2003;  1 1-30
• 48 The European, Israeli Study Group on highly purified hMG versus rFSH . Efficacy and safety of highly purified menotropin versus recombinant follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection cycles: a randomized, comparative trial.  Fertil Steril. 2002;  78 520-528
• 49 Gordon U D, Harrison R F, Fawzy M, Hennely B, Gordon A C. A randomized prospective assessor-blind evaluation of lutenizing hormone dosage and in vitro fertilization outcome.  Fertil Steril. 2001;  75 324-331
• 50 Ng E HY, Lau E YL, Yeung W SB, Ho P C. HMG is as good as recombinant FSH in terms of oocyte and embryo quality: a prospective randomized trial.  Hum Reprod. 2001;  16 319-325
• 51 Kobayashi M, Nakano R, Ooshima A. Immunohistochemical localization of pituitary gonadotrophins and gonadal steroids confirms the “two-cell, two-gonadotrophin” hypothesis of steroidogenesis in the human ovary.  J Endocrinol. 1990;  126 483-488
• 52 Shoham Z, Balen A, Patel A, Jacobs H S. Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients.  Fertil Steril. 1991;  56 1048-1053
• 53 Schoot D C, Harlin J, Shoham Z, Mannaerts B M, Lahlou N, Bouchard P. Recombinant human follicle-stimulating hormone and ovarian response in gonadotropin-deficient women.  Hum Reprod. 1994;  9 1237-1242
• 54 Balasch J, Miro F, Burzaco I, Casamitjana R, Civico S, Ballesca J L. The role of luteinizing hormone in human follicle development and oocyte fertility: Evidence from in-vitro fertilization in a woman with long-standing hypogonadotrophic hypogonadism and using recombinant human follicle stimulating hormone.  Hum Reprod. 1995;  10 1678-1683
• 55 Chappel S C, Howles C. Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process.  Hum Reprod. 1991;  6 1206-1212
• 56 Greb R R, Grieshaber K, Sonntag B, Kiesel L. Medikamentöse Therapieansätze bei Sterilität.  Geburtsh Frauenheilk. 2004;  64 R33-R52
• 57 Westergaard L G, Laursen S B, Yding A C. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction.  Hum Reprod. 2000;  15 1003-1008
• 58 Stanger J D, Yovich J L. Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase.  Brit J Obstet Gynaecol. 1985;  92 385-393
• 59 Howles C M, Macnamee M C, Edwards R G. Short term use of an LHRH agonist to treat poor responders entering an in-vitro fertilization program.  Hum Reprod. 1987;  2 655-656
• 60 Homburg R, Armar N A, Eshel A, Adams J, Jacobs H S. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome.  BMJ. 1988;  297 1024-1026
• 61 Regan L, Owen E J, Jacobs H S. Hypersecretion of luteinising hormone, infertility, and miscarriage.  Lancet. 1990;  336 1141-1144
• 62 Nayudu P L, Lopata A, Jones G M, Cook D A, Bourne H M, Sheater S J, Brown T C, Johnson W I. An analysis of human oocytes and follicles from stimulated cicles: oocyte morphology and associated follicular fluid characteristics.  Hum Reprod. 1989;  4 558-567
• 63 De Loos F, Kastrop P, van Maurik P, van Benedden T H, Kruip T AM. Heterologous cell contacts and metabolic coupling in bovine cumulus oocyte complexes.  Mol Reprod Dev. 1991;  28 255-259
• 64 Sutton M L, Gilchrist R B, Thompson J G. Effects of in vitro environments on the metabolism of the cumulus-oocyte complex and its influence on oocyte developmental capacity.  Hum Reprod Update. 2003;  9 35-48
• 65 Siebzehnrübl E, Kohl J, Dittrich R, Wild L. Freezing of human ovarian tissue - not the oocytes but the granulosa is the problem.  Mol Cell Endocrinol. 2000;  169 109-111
• 66 Hodgen G D. The dominant ovarian follicle.  Fertil Steril. 1982;  38 281-300